Meropenem Venus Pharma

Meropenem, the active ingredient in Meropenem Venus Pharma, is a carbapenem antibiotic presented as an injectable powder for solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis and septicemia in hospitalized patients.

GNH USA supplies Meropenem Venus Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU GMP standards and provides reliable cold‑chain logistics for injectable medicines. Clients benefit from consistent quality, regulatory compliance and responsive technical support.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: achieves bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. Complicated urinary tract infections: eliminates resistant uropathogens and resolves infection symptoms. Nosocomial pneumonia: provides effective coverage against multidrug‑resistant respiratory pathogens. Meningitis: penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms. Septicemia: rapidly clears bloodstream infections caused by Gram‑negative and Gram‑positive bacteria.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset occurring in many patients. - Diarrhea: may be watery and self‑limiting. - Rash or pruritus: skin irritation or mild allergic reaction. - Headache: transient and usually resolves without intervention. - Elevated liver enzymes: mild, transient increase in hepatic transaminases. - Injection site discomfort: pain or erythema at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: antibiotic‑associated severe diarrhea. - Renal toxicity: acute kidney injury in susceptible individuals. - Hematologic effects: neutropenia, thrombocytopenia, or anemia. - Hepatotoxicity: rare cases of significant liver injury.

Precautions should be observed to ensure safe use of Meropenem.

Renal function: adjust dosing in patients with impaired renal clearance. Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. Seizure risk: monitor patients with a history of seizures or receiving CNS‑active drugs. Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. Drug interactions: review concomitant medications for possible interactions. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several concomitant medicines; careful review is recommended.

Major Interactions (Avoid): - Valproic acid: increased risk of seizures when combined. - CNS depressants: additive effect on seizure threshold. - Nephrotoxic agents: heightened potential for renal injury.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes and renal function. - Aminoglycosides: assess for cumulative nephrotoxicity. - Probenecid: may alter renal clearance of meropenem.